News Juno halts CAR-T trial again after 2 more deaths Doubts over Juno CAR-T therapy after two more trial deaths.
News Adaptimmune revives ovarian cancer trial T-cell trial will include controversial chemo agent fludarabine.
Views & Analysis Novartis committed to CAR-Ts - but doubts about commercial v... Novartis may have concerns about commercial prospects, says expert.
Sales & Marketing FH25: Individual centric investing with Steve Seuntjens In a new FH25 podcast episode, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
